Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
| Autor: | Janet Munroe, Heather R. Williams, Yannan J. Wang, Anna Gaidis, Joseph White, Bogna N. Brzezinska, Bhavi Patel, Bunja Rungruang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Immune checkpoint inhibitors education Case Report Pembrolizumab lcsh:Gynecology and obstetrics lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Internal medicine Uterine leiomyosarcoma Overall survival medicine neoplasms lcsh:RG1-991 030219 obstetrics & reproductive medicine business.industry Obstetrics and Gynecology Microsatellite instability medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens digestive system diseases 030220 oncology & carcinogenesis business |
| Zdroj: | Gynecologic Oncology Reports, Vol 35, Iss, Pp 100701-(2021) Gynecologic Oncology Reports |
| ISSN: | 2352-5789 |
| Popis: | Highlights • Overall prognosis of uterine leiomyosarcoma (ULMS) is poor with a low 5-year survival rate. • Microsatellite instability (MSI)-high ULMS is not well documented in current literature. • Immune checkpoint inhibitors such as pembrolizumab have been shown to have good efficacy in treating MSI-high solid tumors. • Targeting MSI-high ULMS with pembrolizumab can potentially maintain a patient’s quality of life and extend overall survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|